Please assess the completion status of the following clinical trial:

Trial Title: Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria: (Before the test, all the subjects required for meeting the entry requirements before they join the group)~* female patients;~* The preoperative core needle biopsy or open surgical excision biopsy diagnosis as breast cancer;~* tumor diameter ≤ 3cm;~* No clinical examination of suspicious axillary lymph node-positive;~* diagnosed clinical conditions can be directly surgery as I, II breast cancer patients;~* preoperative clinical or radiologic evidence without distant metastases (M0);~* signed informed consent.~Exclusion criteria: (Before the test, the subjects under any one of items to meet the requirements can not be enrolled)~* Sentinel lymph node biopsy history had received surgery or axillary area;~* multi-center breast cancer or multiple lesions;~* clinical axillary lymph node metastasis have been found;~* mammary area had received neoadjuvant chemotherapy or radiotherapy;~* inflammatory breast cancer;~* pregnancy;~* no personal freedom and independent civil capacity.~Exclusion criteria: (trials, subjects necessary to meet the requirements of any one item, exit the clinical trial research.)~* severe allergic reaction occurs;~* persistent allergic reaction;~* subjects were required to withdraw from a clinical trial;~* researchers consider it not appropriate to continue to participate in the clinical trial investigator.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indocyanine green & methylene blue, (Type: EXPERIMENTAL): Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1% Indocyanine green with 1ml of 0.5%

Based on this trial design, predict the completion outcome and termination type (if applicable).